Theravance Biopharma (NASDAQ:TBPH) Issues Earnings Results

Theravance Biopharma (NASDAQ:TBPH) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.16), Zacks reports. Theravance Biopharma had a negative return on equity of 24.23% and a negative net margin of 78.18%. The business had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share.

Theravance Biopharma Stock Up 11.2 %

Theravance Biopharma stock traded up $1.00 during midday trading on Wednesday, reaching $9.91. The stock had a trading volume of 168,996 shares, compared to its average volume of 345,809. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $11.71. The company has a fifty day moving average of $8.32 and a 200 day moving average of $8.68. The firm has a market cap of $484.82 million, a price-to-earnings ratio of -9.92 and a beta of 0.25.

Wall Street Analyst Weigh In

TBPH has been the topic of a number of recent research reports. TD Cowen decreased their target price on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th. Leerink Partners downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. Leerink Partnrs cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Finally, StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.